Tozasertib (VX-680, MK-0457)

For research use only.

Catalog No.S1048

76 publications

Tozasertib (VX-680, MK-0457) Chemical Structure

Molecular Weight(MW): 464.59

Tozasertib (VX-680, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with Kiapp of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. Phase 2.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 134 In stock
USD 97 In stock
USD 147 In stock
USD 370 In stock
USD 470 In stock
USD 527 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Tozasertib (VX-680, MK-0457) has been cited by 76 publications

Purity & Quality Control

Choose Selective Aurora Kinase Inhibitors

Biological Activity

Description Tozasertib (VX-680, MK-0457) is a pan-Aurora inhibitor, mostly against Aurora A with Kiapp of 0.6 nM in a cell-free assay, less potent towards Aurora B/Aurora C and 100-fold more selective for Aurora A than 55 other kinases. Phase 2.
Targets
Aurora A [1]
(Cell-free assay)
Aurora C [1]
(Cell-free assay)
Aurora B [1]
(Cell-free assay)
FLT3 [4]
(Cell-free assay)
Bcr-Abl [4]
(Cell-free assay)
0.6 nM(Ki app) 4.6 nM(Ki app) 18 nM(Ki app) 30 nM(Ki) 30 nM(Ki)
In vitro

Although its multi-kinase profile, VX-680 induces similar cytotoxicity with IC50 of approximately 300 nM and exhibits an AUR B-like inhibitory phenotype of G2/M arrest, endoreduplication and apoptosis in BaF3 cells transfected with ABL or FLT-3 (mutant and wild type) kinases. VX-680 prevents the CAL-62 proliferation in a time-dependent manner. VX-680 treatment for 14 days significantly decreases the number and size of colonies by approximately 70% in the 8305C and 90% in the CAL-62, 8505C and BHT-101. Treatment of the different ATC cells with VX-680 inhibits proliferation with the IC50 between 25 and 150  nM. The VX-680 significantly impairs the ability of the different cell lines to form colonies in soft agar. Analysis of caspase-3 activity indicates that VX-680 induces apoptosis in the different cell lines. CAL-62 cells exposed for 12  hours to VX-680 showed an accumulation of cells with ≥4N DNA content. Time-lapse analysis demonstrates that VX-680-treated CAL-62 cells exit metaphase without dividing. Moreover, histone H3 phosphorylation is abrogated following VX-680 treatment. [2] VX-680 has significant inhibitory activity against BCR-Abl bearing the T315I mutation in patient-derived samples. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BE-13 NI\JR4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2faSGlEPTB;MD6wNFM{QCEQvF2= NHrSbGdUSU6JUlXS
RS4-11 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkL5TWM2OD1yLkCwOFA1KM7:TR?= MVzTRW5IWkWU
MFH-ino M1HIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3pW214UUN3ME2wMlAxQTlizszN MnTjV2FPT1KHUh?=
NTERA-S-cl-D1 NEnRXVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFW3NoNKSzVyPUCuNFE1OzRizszN MXPTRW5IWkWU
697 NF;ifnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnmxTWM2OD1yLkCyOFcyKM7:TR?= MULTRW5IWkWU
NALM-6 M1y3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTBwMEK1OVIh|ryP M{i5eHNCVkeURWK=
ES8 NXHDXHA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTBwMES2NVMh|ryP MWXTRW5IWkWU
HUTU-80 MnnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzaTFVKSzVyPUCuNFUzQTlizszN MUDTRW5IWkWU
MV-4-11 MmLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUf4UIZuUUN3ME2wMlA4Pzh{IN88US=> MV;TRW5IWkWU
MONO-MAC-6 M37kS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTBwMEe4O|kh|ryP NHzTSWxUSU6JUlXS
LC-2-ad M4DGXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXGeYZuUUN3ME2wMlA5Pzh7IN88US=> NWTNTGhxW0GQR2LFVi=>
BL-41 NFXuV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jHeGlEPTB;MD6xNFQ1PSEQvF2= Mon5V2FPT1KHUh?=
A4-Fuk NH;DfnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwMUG1OlMh|ryP NUeyR|FxW0GQR2LFVi=>
SW954 MoPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTBwMUKyNlkh|ryP MkfYV2FPT1KHUh?=
BV-173 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknFTWM2OD1yLkGyOlQyKM7:TR?= NILhTmhUSU6JUlXS
TE-11 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXITWM2OD1yLkG0PVgzKM7:TR?= M{TLc3NCVkeURWK=
SK-UT-1 NF[5RnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwMUW5OlUh|ryP NH7FfphUSU6JUlXS
SIG-M5 MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHiTmpKSzVyPUCuNVY4ODdizszN NUPD[2pnW0GQR2LFVi=>
OCUB-M MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXYR2NKSzVyPUCuNVY6QDNizszN M1jBWHNCVkeURWK=
K052 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfaVmtKSzVyPUCuNVk1QCEQvF2= MYPTRW5IWkWU
VA-ES-BJ M3;PNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTBwMkCwPFYh|ryP M2eyfHNCVkeURWK=
SW982 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\MdG9KSzVyPUCuNlE{QCEQvF2= MVnTRW5IWkWU
LB647-SCLC NH;MV49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2CwfWlEPTB;MD6yNVUzOyEQvF2= MkjyV2FPT1KHUh?=
PSN1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPpTWM2OD1yLkKyNFI3KM7:TR?= MUjTRW5IWkWU
BB30-HNC NYfCO5lmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\1TWM2OD1yLkKyOVkyKM7:TR?= NWDDT2NkW0GQR2LFVi=>
ST486 MofVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTBTWM2OD1yLkKzNFg4KM7:TR?= MomzV2FPT1KHUh?=
MOLT-4 NWWxU5J3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2Xqd2lEPTB;MD6yN|M{PyEQvF2= MXPTRW5IWkWU
EW-16 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTBwMkO3Olgh|ryP Mn3FV2FPT1KHUh?=
KS-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInBVHJKSzVyPUCuNlM4QDVizszN NGDzN3RUSU6JUlXS
SR NIe0R4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYT4b4VUUUN3ME2wMlI1PTZ2IN88US=> MWHTRW5IWkWU
KM12 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwMk[zOkDPxE1? M2XU[HNCVkeURWK=
EM-2 MkDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlX1TWM2OD1yLkK2OlQyKM7:TR?= M3HX[HNCVkeURWK=
MEG-01 NFPHelJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnaTWM2OD1yLkK3PFQ6KM7:TR?= NUfvXllFW0GQR2LFVi=>
NB13 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPiNmNKSzVyPUCuNlc6QDRizszN NWLsfXBJW0GQR2LFVi=>
RKO MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwM{C4NVMh|ryP M1O3d3NCVkeURWK=
CESS MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHq3NXVKSzVyPUCuN|E{OjhizszN NXKzO|V1W0GQR2LFVi=>
EoL-1-cell NVuxOVQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\t[mlEPTB;MD6zN|Q2QSEQvF2= M1uxeHNCVkeURWK=
DOHH-2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;kV2lEPTB;MD6zN|c5OSEQvF2= NUX2cnNDW0GQR2LFVi=>
A388 M2LtV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTBwM{SwPFYh|ryP MonhV2FPT1KHUh?=
LAMA-84 MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTBwM{WxO|gh|ryP M1XENXNCVkeURWK=
IMR-5 NVXTcXhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;CVGtCUUN3ME2wMlM2PTRizszN MXfTRW5IWkWU
KARPAS-422 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3OTWM2OD1yLkO3NlczKM7:TR?= NFm4ToZUSU6JUlXS
MRK-nu-1 MorxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2D3NWlEPTB;MD6zPFE{KM7:TR?= NIrtUJVUSU6JUlXS
BL-70 MofDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPUU3NNUUN3ME2wMlM5QTd2IN88US=> NH7HbJNUSU6JUlXS
LXF-289 MlXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTBwNEC0NFYh|ryP MWTTRW5IWkWU
RL95-2 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDxWVR2UUN3ME2wMlQxPTZ5IN88US=> NHi1NJJUSU6JUlXS
QIMR-WIL Mnf0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXReoMzUUN3ME2wMlQzPjd4IN88US=> MV3TRW5IWkWU
K-562 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDTdGRXUUN3ME2wMlQ{PDd{IN88US=> M1ewN3NCVkeURWK=
NCI-H510A Ml7SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInSbohKSzVyPUCuOFM5OjNizszN NX\V[4ZwW0GQR2LFVi=>
NCI-H524 NWDyUHZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwNUGxOFch|ryP M3ywbXNCVkeURWK=
KE-37 NVTNNoFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\JZWlEPTB;MD61NlExOiEQvF2= NYnNUFRNW0GQR2LFVi=>
KP-N-YS MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwNUSzPVIh|ryP NUnScYhrW0GQR2LFVi=>
LS-411N MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTBwNUe3OVIh|ryP MUnTRW5IWkWU
CTV-1 M2nxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTodpN5UUN3ME2wMlU5Pzd|IN88US=> NEXVV5JUSU6JUlXS
NCI-SNU-16 MlHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVX2S2hvUUN3ME2wMlY{PTdzIN88US=> MUHTRW5IWkWU
HT-144 NEH3TIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTBwNkO3PVgh|ryP NXfuTHk1W0GQR2LFVi=>
NCI-H187 Ml;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fmb2lEPTB;MD62OFE{KM7:TR?= MUPTRW5IWkWU
OCI-AML2 NIOzVGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHIXHo4UUN3ME2wMlY1PDB|IN88US=> NFLFUINUSU6JUlXS
CCRF-CEM M2XnSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTBwNkWzOFYh|ryP NID5SYVUSU6JUlXS
ONS-76 NFi3RYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnMTWM2OD1yLk[2OFU5KM7:TR?= NGPQcWxUSU6JUlXS
IST-SL2 MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwN{G5PFIh|ryP NVPzXoVkW0GQR2LFVi=>
NB6 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlf6TWM2OD1yLke3NlU1KM7:TR?= MljiV2FPT1KHUh?=
SK-PN-DW NVy3d|N2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\0c3JKSzVyPUCuO|kyPCEQvF2= MnLPV2FPT1KHUh?=
HCC1599 NF;HOIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\vd2pKSzVyPUCuPFA5PzRizszN MWnTRW5IWkWU
MC116 NGSwdFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfST2pUUUN3ME2wMlg2ODFzIN88US=> MlnCV2FPT1KHUh?=
TE-15 M3;T[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml:0TWM2OD1yLki1NFk5KM7:TR?= M4[2THNCVkeURWK=
HOP-62 MkjHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzWTWM2OD1yLki2N|I6KM7:TR?= NIPYcYlUSU6JUlXS
TGBC24TKB M{jBO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPnN5I5UUN3ME2wMlg3Ozh3IN88US=> NX75bZdQW0GQR2LFVi=>
HCE-4 NFT5XZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwOEiwOlMh|ryP M2jqR3NCVkeURWK=
ALL-PO Ml\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rGVmlEPTB;MD64PFE4PSEQvF2= MnX2V2FPT1KHUh?=
KGN NWS5[HVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LQZ2lEPTB;MD64PVk6PSEQvF2= NXzGXZVVW0GQR2LFVi=>
ML-2 M1zYU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrJSXpKSzVyPUCuPVAzPTlizszN MlX2V2FPT1KHUh?=
ES4 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXBZY1RUUN3ME2wMlkyOTJ6IN88US=> Ml\CV2FPT1KHUh?=
SF126 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MULJR|UxRTBwOUS4NVkh|ryP NIexZ3BUSU6JUlXS
SK-N-DZ M4LGe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M33BbWlEPTB;MD65OlE5QSEQvF2= MWLTRW5IWkWU
HCC1187 M3\wXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzxW|lKSzVyPUGuNFA2ODVizszN NHHrOWVUSU6JUlXS
DU-4475 NIeyfIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTFwMEG3OVYh|ryP NXTBSFJzW0GQR2LFVi=>
NKM-1 MnfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTFwMEK3O|Uh|ryP Ml:zV2FPT1KHUh?=
HL-60 NGi1e|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrPPZpuUUN3ME2xMlA3PTd2IN88US=> NV:4OndpW0GQR2LFVi=>
SBC-1 M3e3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3TE[WlEPTB;MT6xNlU1OiEQvF2= MX\TRW5IWkWU
TE-10 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTFwMUK5OFYh|ryP M3L2VnNCVkeURWK=
ETK-1 Ml\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;I[YlrUUN3ME2xMlE{PjF|IN88US=> NWfObFhJW0GQR2LFVi=>
HAL-01 Ml3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37zR2lEPTB;MT6xOlcxQSEQvF2= MY\TRW5IWkWU
BB65-RCC MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PGNGlEPTB;MT6xPFAxPSEQvF2= MUTTRW5IWkWU
EW-1 NV\zNGVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HaXGlEPTB;MT6xPFU3OiEQvF2= MWXTRW5IWkWU
SK-NEP-1 Mmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEi5VWhKSzVyPUGuNlEyOTFizszN NGDNNYJUSU6JUlXS
SK-LMS-1 NUDTOXVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWe2WFZ{UUN3ME2xMlIzOjF{IN88US=> MWDTRW5IWkWU
DEL M1;hcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1u2[GlEPTB;MT6yOVY1OyEQvF2= Mn;hV2FPT1KHUh?=
GT3TKB MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7TWlRIUUN3ME2xMlI5ODV5IN88US=> MkjtV2FPT1KHUh?=
MOLT-16 NVvKfYlrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHKZolKSzVyPUGuN|U1ODVizszN MUPTRW5IWkWU
CMK NGjqXHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vGO2lEPTB;MT60NlEyPyEQvF2= MnLiV2FPT1KHUh?=
NB5 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTFwNkSyNlkh|ryP Mkf4V2FPT1KHUh?=
NCI-H1963 MnzDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TySWlEPTB;MT63NFU5OyEQvF2= MUnTRW5IWkWU
KURAMOCHI NWLsUJdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoS2TWM2OD1zLke4PVEyKM7:TR?= M1fRc3NCVkeURWK=
TE-8 NE\4R3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYCyW2E5UUN3ME2xMlgxOzZ6IN88US=> M370Z3NCVkeURWK=
NCI-H1304 NWjNeFhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jPfWlEPTB;MT64N|A4OyEQvF2= MVzTRW5IWkWU
A101D NGnpS4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWrJR|UxRTFwOEezPVUh|ryP NG\5UJlUSU6JUlXS
SCLC-21H NWX4b4k2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PwUWlEPTB;MT65O|A2PyEQvF2= NV3XRnE2W0GQR2LFVi=>
GB-1 NX7Z[4lsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTJwMEG2OFch|ryP MWLTRW5IWkWU
KARPAS-45 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXEUHhKSzVyPUKuNFI3PTRizszN NXHSb2lNW0GQR2LFVi=>
ATN-1 NX7BNXNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{L1NWlEPTB;Mj6wNlg2QCEQvF2= MnXkV2FPT1KHUh?=
NCI-H720 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTONZlkUUN3ME2yMlA3OjR2IN88US=> NUXhfoVYW0GQR2LFVi=>
RPMI-6666 Ml7pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTJwMU[yNFch|ryP MoPpV2FPT1KHUh?=
NB17 NHX4U3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvITWM2OD1{LkK5Nlch|ryP NV;Ue5ZyW0GQR2LFVi=>
IST-SL1 NXjZSlhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1z6[GlEPTB;Mj6yPVc3PSEQvF2= MlXIV2FPT1KHUh?=
SH-4 NV7UbHlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\RN2lEPTB;Mj6zNlQ3QSEQvF2= NFTZPYFUSU6JUlXS
K5 NEHhSYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnPdlhKSzVyPUKuOFA{OTlizszN NFPkXGhUSU6JUlXS
OVCAR-4 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TSSGlEPTB;Mj60OlE{KM7:TR?= M33aOXNCVkeURWK=
ACN NX7kRmlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEC0bnFKSzVyPUKuOVAzOTNizszN MXzTRW5IWkWU
TGW MmnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrCTWM2OD1{Lk[1PFMzKM7:TR?= NEPSU4hUSU6JUlXS
NCI-H2107 MoTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlviTWM2OD1{LkizO|EyKM7:TR?= MVrTRW5IWkWU
NCI-H82 Mn3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTJwOEO4N|gh|ryP NGrQNXpUSU6JUlXS
SK-N-FI MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jqb2lEPTB;Mj64Olg3QCEQvF2= NYi4OYZZW0GQR2LFVi=>
LB1047-RCC MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLDXlY3UUN3ME2yMlg5OTJ4IN88US=> M3fHXnNCVkeURWK=
LU-134-A M1[5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTJwOEmyOkDPxE1? NIjhfHJUSU6JUlXS
NCI-H209 MkDDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX\4UIliUUN3ME2yMlkyOjV|IN88US=> M{D1bXNCVkeURWK=
NOMO-1 MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYH3SYZ1UUN3ME2zMlAzOjd2IN88US=> MnvhV2FPT1KHUh?=
RH-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1Py[GlEPTB;Mz6xO|I6OSEQvF2= NF7XbnpUSU6JUlXS
LOUCY MkW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjyelhkUUN3ME2zMlE5Pjl|IN88US=> NVn5WHp5W0GQR2LFVi=>
TE-9 MknDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHy1No9KSzVyPUOuNlY4OzZizszN MVjTRW5IWkWU
PF-382 M3fPNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mni4TWM2OD1|LkO1O|c5KM7:TR?= M{LLbnNCVkeURWK=
RPMI-8402 MnSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTNwNUi2NFMh|ryP MV\TRW5IWkWU
HEL NH;6TWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjmXZo2UUN3ME2zMlY{OiEQvF2= MkLUV2FPT1KHUh?=
NOS-1 NHHRTHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTNwOES3OVQh|ryP NVrnelhnW0GQR2LFVi=>
ES1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLpTWM2OD1|LkmyNlk{KM7:TR?= NGPPRXpUSU6JUlXS
NCI-H2171 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTNwOUK0NlMh|ryP MoP5V2FPT1KHUh?=
NCI-H747 NGq3TFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTNwOUSyNlEh|ryP NYTXSWVCW0GQR2LFVi=>
MHH-NB-11 M4nSb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M16zb2lEPTB;Mz65OVMyOiEQvF2= NHK3NlJUSU6JUlXS
MZ1-PC MoHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETUOVdKSzVyPUOuPVkzPCEQvF2= NHvRUZNUSU6JUlXS
MMAC-SF NHnx[GhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTRwMEK0Olch|ryP NH:0N4FUSU6JUlXS
NMC-G1 NE[zNXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPaPVA1UUN3ME20MlIzPzJ|IN88US=> MUHTRW5IWkWU
SW872 NVLUSINUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGG5V4VKSzVyPUSuN|Q{PCEQvF2= M37Y[XNCVkeURWK=
TE-12 MoDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTRwNU[zPVQh|ryP M1vHVnNCVkeURWK=
LU-139 MlvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTRwNkG4N|Uh|ryP Mn3FV2FPT1KHUh?=
HC-1 MkXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG[0[JFKSzVyPUSuOlk1QTRizszN M{[yU3NCVkeURWK=
COR-L279 MmWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTRwN{W4PVEh|ryP MkW5V2FPT1KHUh?=
SF268 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvuTWM2OD12Lke5PVE3KM7:TR?= M4LWXHNCVkeURWK=
MC-CAR NH3L[ZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnNPZNZUUN3ME21MlA3PzV5IN88US=> MmXDV2FPT1KHUh?=
TK10 MkLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTVwM{W0Olkh|ryP MmDKV2FPT1KHUh?=
TE-1 NHrCZmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;aSIJbUUN3ME21MlQ6ODB2IN88US=> NHzNNmdUSU6JUlXS
NCI-H2126 Mk\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHX3RYZKSzVyPUWuOlQ2PzRizszN NH7RTXNUSU6JUlXS
Daudi NWXFSno6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLHVZRkUUN3ME21MlY6OTJizszN M4S5O3NCVkeURWK=
NCI-H1648 NHXOSldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrkTWM2OD13LkixOFU1KM7:TR?= M1PDVnNCVkeURWK=
OS-RC-2 NWj3T2lYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTVwOUi1PVch|ryP NETQVoNUSU6JUlXS
DJM-1 NXThWYROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPaTWM2OD14LkO0OlY3KM7:TR?= M2jJOnNCVkeURWK=
LS-1034 MkPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrWXYlKSzVyPU[uO|U3PiEQvF2= NFO2eolUSU6JUlXS
NCI-H1581 MlrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTZwN{i0NFUh|ryP MnrxV2FPT1KHUh?=
UACC-257 M4HFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{G5cGlEPTB;Nz6wOFUyOiEQvF2= M1jRSXNCVkeURWK=
KM-H2 NFq4bWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWLJR|UxRTdwMUi0OVch|ryP MYfTRW5IWkWU
NCI-H1436 NWjqR25[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{P5ZmlEPTB;Nz62PVk{OiEQvF2= MmHRV2FPT1KHUh?=
IA-LM MmWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{S4WmlEPTB;Nz64OVkh|ryP Mn\sV2FPT1KHUh?=
NCI-H526 M3HaXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\MS5BKSzVyPUiuNlU3OzdizszN MoLXV2FPT1KHUh?=
GCIY M2HseGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4[3N2lEPTB;OD6zOlk3PSEQvF2= NHTISJlUSU6JUlXS
CP67-MEL NYDSXWtzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmT0TWM2OD16LkWzNlYh|ryP Mn60V2FPT1KHUh?=
KALS-1 M3vzUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fEe2lEPTB;OD64N|g2OSEQvF2= M2C1fnNCVkeURWK=
NCI-H1770 M330XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmP1TWM2OD16LkmwNlY2KM7:TR?= NFHkOY9USU6JUlXS
8-MG-BA M1HzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTlwM{K4OFQh|ryP NUDNNmdZW0GQR2LFVi=>
KY821 NGfofZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rZVmlEPTB;OT63O|Q5PCEQvF2= NHnaTGhUSU6JUlXS
SNB75 NF\tWolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3ITWM2OD1zMD6wO|Yh|ryP MW\TRW5IWkWU
NCCIT NXHPbmo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[2TWM2OD1zMT6wOVgzKM7:TR?= MWjTRW5IWkWU
SJSA-1 M1vQfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELycVVKSzVyPUGxMlI5QTFizszN M3j6cnNCVkeURWK=
LB373-MEL-D NITmOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYn6c4h2UUN3ME2xNU4{QDJ5IN88US=> NG\hZXZUSU6JUlXS
TALL-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHz[oRKSzVyPUGxMlQxPThizszN NEHSOWhUSU6JUlXS
NB69 NEPweoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDXS3ZKSzVyPUGxMlc4ODVizszN MXrTRW5IWkWU
NCI-H1355 M1jXb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfpbWd1UUN3ME2xNU46PDJ4IN88US=> NH3JXpJUSU6JUlXS
DMS-153 M1XLXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWS4dIhCUUN3ME2xNk4xPDJ4IN88US=> MnP0V2FPT1KHUh?=
OPM-2 NXTk[pdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3XTWJ2UUN3ME2xNk4yPTl4IN88US=> NXPjfGFTW0GQR2LFVi=>
NB1 NYf5fFZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHCVWhKSzVyPUGyMlI6KM7:TR?= NUnPTZpsW0GQR2LFVi=>
A3-KAW NEXnUGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTF{LkOyN|Yh|ryP NVT0W|RxW0GQR2LFVi=>
NCI-H1882 M{nPTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvkU4R2UUN3ME2xNk41ODZ4IN88US=> NIHv[I5USU6JUlXS
KG-1 NWD1UoVbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX35NW41UUN3ME2xNk43PTR3IN88US=> MYjTRW5IWkWU
LC4-1 MlTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID1dGNKSzVyPUGyMlc4ODZizszN M3\CRnNCVkeURWK=
HCE-T M4flRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTF|LkCwOFkh|ryP NYXTRXk3W0GQR2LFVi=>
NEC8 NYryUZJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPZTWM2OD1zMz6xNFM5KM7:TR?= NEC3OpBUSU6JUlXS
IST-MEL1 NG[4OndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mne0TWM2OD1zMz61O|g5KM7:TR?= M4fhRXNCVkeURWK=
EW-3 NFnheVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIe3emFKSzVyPUGzMlc1ODJizszN NVzLU4VtW0GQR2LFVi=>
CTB-1 NVvoVWt4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDi[pdKSzVyPUG0MlA{OjlizszN M3j0VnNCVkeURWK=
LS-123 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnflTWM2OD1zND6xOVg5KM7:TR?= NUDqbnQ5W0GQR2LFVi=>
NCI-H1417 NUn1do1pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLCOnNmUUN3ME2xOE4{ODV{IN88US=> MVvTRW5IWkWU
MZ7-mel NEi1VWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;lVVBmUUN3ME2xOE41PDN|IN88US=> M2PjXHNCVkeURWK=
JiyoyeP-2003 M{HzVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWn4RXhZUUN3ME2xOU43OzJ4IN88US=> M1rBc3NCVkeURWK=
ES6 Mlv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVLsXIhnUUN3ME2xOk4zOzZzIN88US=> MYDTRW5IWkWU
HH M1LkPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\aOmdKSzVyPUG3MlE6PjNizszN MX;TRW5IWkWU
SF539 NVm4dXpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LneWlEPTB;MUeuPVkzOiEQvF2= MnXoV2FPT1KHUh?=
Calu-6 MoG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7YTWM2OD1zOT6yN|kh|ryP NWTDbJpNW0GQR2LFVi=>
SK-MM-2 NIH0PHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\mTWM2OD1zOT61OVUh|ryP NF25dW1USU6JUlXS
IST-MES1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV:y[|U2UUN3ME2xPU43PjZ|IN88US=> NHO4d4tUSU6JUlXS
GI-ME-N M4Ptfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DFNWlEPTB;MUmuPFIzPyEQvF2= M1f6d3NCVkeURWK=
CAL-148 NEXh[5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3JTWM2OD1{MD65PVM1KM7:TR?= MUTTRW5IWkWU
EVSA-T M4nJXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXHUpN4UUN3ME2yNU4yPDl7IN88US=> NHn6dJhUSU6JUlXS
LP-1 M2LTcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TEOmlEPTB;MkGuN|Q{OiEQvF2= M4LNRnNCVkeURWK=
BOKU MlPpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXLTWM2OD1{MT60OVM{KM7:TR?= Ml:wV2FPT1KHUh?=
KLE MmfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVu3Xo02UUN3ME2yNk4yQTB|IN88US=> MXzTRW5IWkWU
LB831-BLC MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;BdmxKSzVyPUK1MlE2OjZizszN NFj6N3hUSU6JUlXS
NCI-H889 Ml3VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXvTWM2OD1{NT6xPVMyKM7:TR?= M3;FTHNCVkeURWK=
REH NEXobJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\ZdGlEPTB;MkWuOFY4OSEQvF2= MnTiV2FPT1KHUh?=
KP-N-RT-BM-1 MojXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTJ3LkS3OVIh|ryP NYDwfGVMW0GQR2LFVi=>
MPP-89 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTJ3LkWzNVQh|ryP NYTjS5NGW0GQR2LFVi=>
no-11 NGDaOHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjQTWM2OD1{NT63OFch|ryP NWnQWW5PW0GQR2LFVi=>
NCI-H748 M1myXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTQXIdDUUN3ME2yOU44PjJ5IN88US=> MV7TRW5IWkWU
LB2518-MEL M4PMbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\DTWM2OD1{Nz6xO|c{KM7:TR?= NGf1e45USU6JUlXS
TGBC1TKB Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjJPVZmUUN3ME2yO{42PTh3IN88US=> MlH2V2FPT1KHUh?=
MHH-PREB-1 NV2y[21ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{X6d2lEPTB;MkiuNFc{PCEQvF2= Ml7RV2FPT1KHUh?=
MZ2-MEL MlrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PxXmlEPTB;MkiuOlE1OyEQvF2= NYTLfXRyW0GQR2LFVi=>
U-266 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDNdoJKUUN3ME2yPE43OzZ4IN88US=> NXHmOIN1W0GQR2LFVi=>
SNU-C1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJ6Lkm0N{DPxE1? MY\TRW5IWkWU
SW962 MnK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDIW5ZGUUN3ME2zNE4zPzR5IN88US=> M3\SdHNCVkeURWK=
Raji MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTNyLkW1PVIh|ryP MkPJV2FPT1KHUh?=
KNS-42 NIjLdndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTGOIxNUUN3ME2zNE45QTV4IN88US=> MXjTRW5IWkWU
LB996-RCC MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFS4bFJKSzVyPUOxMlE4ODJizszN MXvTRW5IWkWU
CHP-126 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3O[ndKSzVyPUOxMlE6QDRizszN MlvCV2FPT1KHUh?=
RXF393 MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoK0TWM2OD1|Mj60PVch|ryP NIrIOodUSU6JUlXS
COLO-684 M2nxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTN{Lk[0N|gh|ryP NUPoN4p4W0GQR2LFVi=>
A704 NVztS4F2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvvZ4VKSzVyPUOzMlU2OzhizszN M2CyZ3NCVkeURWK=
A253 M4jUNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzuTWM2OD1|Mz61PFUzKM7:TR?= NXLtN5RrW0GQR2LFVi=>
KNS-81-FD NXXJdWJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjFTWM2OD1|ND61OFU3KM7:TR?= MWXTRW5IWkWU
TE-441-T M2LydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTN2Lk[zO|Eh|ryP MX7TRW5IWkWU
HCC2157 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrsVI1CUUN3ME2zOU41PjF7IN88US=> NHOxXYRUSU6JUlXS
ES3 NHHRcpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTN4Lk[3OUDPxE1? NWDh[lFWW0GQR2LFVi=>
NCI-H1155 MlfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7iTWM2OD1|Nz64NVUh|ryP NYnQR4hjW0GQR2LFVi=>
SNU-C2B MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHaR5g5UUN3ME2zPE4yPjV2IN88US=> NXrkdm9EW0GQR2LFVi=>
JAR NV73b21kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFf5U|NKSzVyPUO4MlI1PDlizszN M3\JfXNCVkeURWK=
GDM-1 M1TtNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17KbGlEPTB;M{iuPVEyPiEQvF2= M1;4SXNCVkeURWK=
KU812 NFrj[VBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPEWpFmUUN3ME20NU42ODdizszN Mn3LV2FPT1KHUh?=
BC-1 M{LQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfCb|hSUUN3ME20Nk43PzNzIN88US=> MnPWV2FPT1KHUh?=
GI-1 Ml\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDDcGtKSzVyPUSyMlkyQTJizszN MYnTRW5IWkWU
NCI-H1694 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXvTWM2OD12ND65OFczKM7:TR?= M4m4SHNCVkeURWK=
DG-75 NEfze4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoraTWM2OD12NT6xOVc4KM7:TR?= NYT0cpU{W0GQR2LFVi=>
COR-L88 Mn7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLyTWM2OD12NT6yO|c5KM7:TR?= M3fpcXNCVkeURWK=
LS-513 NX\0NlZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfJ[XFKSzVyPUS1MlkyPTZizszN M1LDc3NCVkeURWK=
HD-MY-Z M2e5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFGzRpNKSzVyPUS2MlQ3OTJizszN MoL4V2FPT1KHUh?=
L-363 NX3kOJRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XYfGlEPTB;NE[uPFgyKM7:TR?= NUPROXNlW0GQR2LFVi=>
TE-6 MmH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;5VGlEPTB;NEiuOFQ3KM7:TR?= M4m5UnNCVkeURWK=
NCI-H345 M3XtOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTBTIFmUUN3ME20PE41PjhizszN MnP2V2FPT1KHUh?=
TE-5 Mm\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG[zTlVKSzVyPUS5MlcyOThizszN M3flTXNCVkeURWK=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
DLK / p-MKK7 / MKK7 / p-JNK / JNK ; 

PubMed: 23431148     


Western blot of the DLK pathway members in RGCs (retinal ganglion cells) 4 h after immunopanning in the presence of 0, 0.03, 0.06, 0.125, 0.25, 0.5, 1, or 2 μM tozasertib. 

p-AURKA / AURKA / Survivin ; 

PubMed: 28218735     


BGC823 cells were incubated with indicated doses of VX-680 for 24 h before subjected to western blotting with the indicated antibodies. Densitometry was used to quantify the Survivin and GAPDH levels. The relative expression shown (right panel) are means±s.e.m. of the ratios of Survivin to GAPDH. 

YAP; 

PubMed: 31160567     


Western blot analysis of YAP protein level in A549 cells treated with indicated doses of VX-680 for 24 h. 

p-AKT / p-GSK3β / Cleaved caspase-3 / Cleaved PARP ; 

PubMed: 21600017     


NB4-R2 cells were collected, lysed and subjected to Western blot analysis with cleaved caspase-3, cleaved-PARP, pAkt-1 (Ser473), pGSK-3β (Ser9) specific antibodies. GAPDH was used as a loading control. Data shown is a representative of three independent experiments.

23431148 28218735 31160567 21600017
Immunofluorescence
α-tubulin / Aurora-A ; 

PubMed: 21600017     


The morphology of mitotic spindle was shown by immunofluorescence staining with anti-α-tubulin antibody and anti-Aur-A antibodies. Microtubules were stained as green, Aur-A protein as red, and nucleus as blue.

21600017
Growth inhibition assay
Cell viability; 

PubMed: 21600017     


VX-680 significantly suppresses the proliferation in a number of leukemic cell types. OCI-AML3, NB4, HL-60 and ML-1 cells were incubated with increasing doses of VX-680 (1, 2, 5 and 10 nM) for 24 hr. Cell viability was measured by MTT assay. Data summarized three independent experiments, *p < 0.05, **p < 0.01, compared to control.

21600017
In vivo VX-680 gives rise to a marked decrease in tumor size in a human AML (HL-60) xenograft model. In mude mice treateed with VX-680 at 75 mg/kg, twice a day intraperitoneally (b.i.d. i.p.) for 13 days, mean tumor volumes are reduced by 98%. Tumor growth decrease is dose dependent and significant at a dose of 12.5 mg/kg b.i.d. VX-680 is well tolerated, with a small decrease in body weight observed only at the highest dose. VX-680 also triggers tumor regresson in pancreatic and colon xenograft models. VX-680 also displays potent antitumor activity when infused i.v. in mude rats bearing established HCT116 tumors. A higher dose of VX-680 (2 mg/kg/h) improves efficacy with a 56% decrease in mean tumor volume. [1]

Protocol

Kinase Assay:

[3]

- Collapse

Kinase inhibition assays:

The consumption of ATP is coupled via the pyruvate kinase/lactic dehydrogenase enzyme pair to the oxidation of NADH, which can be monitored through the decrease in absorption at 340 nm. Reactions contains 100 mM Tris (pH 8), 10 mM MgCl2, 2.2 mM ATP, 1 mM phosphoenolpyruvate, 0.6 mg/mL NADH, 75 units/mL pyruvate kinase, 105 units/mL lactate dehydrogenase, and 0.5 mM substrate peptide (sequence: EAIYAAPFAKKK). Reactions (75 μL) are started by adding sufficient kinase to bring the reactions to 30 nM kinase concentration and the decrease in absorbance is monitored over 30 minutes at 30°C in a microtiter plate spectrophotometer. Inhibitory constants are obtained through addition of 3.75 μL VX-680 in 100% DMSO or DMSO alone. Ki values are calculated as follows, K i = IC50 / (1 + [S]/Kd), where [S] = [ATP] = 2.2 mM, and Kd (of ATP to Abl) = 70 μM. These values are calculated assuming a Kd (ATP) of 70 μM for wild type and H396P Abl kinase domain.
Cell Research:

[2]

- Collapse
  • Cell lines: CAL-62 cells
  • Concentrations: 5-500 nM
  • Incubation Time: 4 days
  • Method:

    The CAL-62 cells are cultured in the absence (dimethyl sulfoxide, DMSO) or the presence of 500  nM VX-680 for different periods of time (1-5 days). The dose-dependent effects of VX-680 on cell proliferation are evaluated by treating the different ATC cells for 4 days with different concentrations of the Aurora inhibitor (5–500  nM). The cells are pulse labeled with 30  mM BrdU for 2  hours before the end of the incubation time. The BrdU incorporation is analyzed by means of a colorimetric immunoassay using the cell proliferation ELISA kit. The results from VX-680-treated cells are compared with those observed in control cells and expressed as a fold of variation versus control.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Female athymic NCr-nu mice bearing HL-60 leukemia cells
  • Dosages: 50 mg/kg, 75 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 93 mg/mL (200.17 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 464.59
Formula

C23H28N8OS

CAS No. 639089-54-6
Storage powder
in solvent
Synonyms N/A
Smiles CN1CCN(CC1)C2=NC(=NC(=C2)NC3=N[NH]C(=C3)C)SC4=CC=C(NC(=O)C5CC5)C=C4

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Aurora Kinase Signaling Pathway Map

Aurora Kinase Inhibitors with Unique Features

Related Aurora Kinase Products

Tags: buy Tozasertib|Tozasertib ic50|Tozasertib price|Tozasertib cost|Tozasertib solubility dmso|Tozasertib purchase|Tozasertib manufacturer|Tozasertib research buy|Tozasertib order|Tozasertib mouse|Tozasertib chemical structure|Tozasertib mw|Tozasertib molecular weight|Tozasertib datasheet|Tozasertib supplier|Tozasertib in vitro|Tozasertib cell line|Tozasertib concentration|Tozasertib nmr|Tozasertib in vivo|Tozasertib clinical trial|Tozasertib inhibitor|Tozasertib Cell Cycle inhibitor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID